Larimar Therapeutics Inc [LRMR] stock is trading at $10.49, up 7.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The LRMR shares have gain 38.21% over the last week, with a monthly amount glided 12.31%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Larimar Therapeutics Inc [NASDAQ: LRMR] stock has seen the most recent analyst activity on April 03, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $25. Previously, Citigroup upgraded its rating to Buy on November 17, 2023, and kept the price target unchanged to $4.50. On October 19, 2022, Guggenheim initiated with a Buy rating and assigned a price target of $12 on the stock. William Blair downgraded its rating to a Mkt Perform. JMP Securities initiated its recommendation with a Mkt Outperform. William Blair started tracking with a Outperform rating for this stock on February 01, 2021, and assigned it a price target of $29.
Larimar Therapeutics Inc [LRMR] stock has fluctuated between $2.18 and $13.68 over the past year. Currently, Wall Street analysts expect the stock to reach $14.5 within the next 12 months. Larimar Therapeutics Inc [NASDAQ: LRMR] shares were valued at $10.49 at the most recent close of the market. An investor can expect a potential return of 38.23% based on the average LRMR price forecast.
Analyzing the LRMR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.36 and Total Capital is -0.22. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.84 points at the first support level, and at 9.20 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.82, and for the 2nd resistance point, it is at 11.16.
Ratios To Look Out For
For context, Larimar Therapeutics Inc’s Current Ratio is 17.99. On the other hand, the Quick Ratio is 17.99, and the Cash Ratio is 8.58.
Transactions by insiders
Recent insider trading involved Flynn James E, Director, that happened on Feb 16 ’24 when 4.29 million shares were purchased. Director, Hamilton Thomas Edward completed a deal on Feb 16 ’24 to buy 57208.0 shares. Meanwhile, Director THOMAS FRANK E bought 2000.0 shares on Feb 14 ’24.
